Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 3704-3710

  Wang, T B ^a   Zhang, N L ^a   Wang, S H ^a   Li, H Y ^a   Chen, S W ^a   Zheng, Y G ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

BRCA1; Non small cell lung cancer; Overall survival; RRM1; RRM2

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; BRCA1 PROTEIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN RRM1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; PLATINUM; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; VERY ELDERLY; BIOSYNTHESIS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900384112     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.May.9.15     Document Type: Article

References (18)

1. Camps C, Sirera R, Iranzo V, Tarón M, et al. (2007). Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin. Lung Cancer 8: 369-375.
2. Crinò L, Weder W, van Meerbeeck J and Felip E (2010). Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl 5): v103-v115.
3. De Dosso S, Zanellato E, Nucifora M, Boldorini R, et al. (2013). ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother. Pharmacol. 72: 159-165.
4. Ginsberg RJ, Kris K and Armstrong G (1993). Cancer of the Lung. In: Principles and Practice of Oncology. 4th edn. (DeVita VT, Hellman S and Rosenberg SA, eds.). JB Lippincott Co., Philadelphia, 673-682.
5. Han Y, Wang XB, Xiao N and Liu ZD (2013). mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac. J. Cancer Prev. 14: 2987-2990.
6. International Agency for Research on Cancer (IARC) (2008). Lung Cancer Incidence, Mortality and Prevalence Worldwide in 2008. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed November 10, 2013.
7. Matakidou A, el Galta R, Webb EL, Rudd MF, et al. (2007). Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum. Mol. Genet. 16: 2333-2340.
8. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981). Reporting results of cancer treatment. Cancer 47: 207-214.
9. Park KW, Jung ES, Kim DG, Yoo YK, et al. (2013). ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma. Cancer Res. Treat. 45: 63-69.
10. Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24: 331-344.
11. Sodja E, Knez L, Kern I, Ovčariček T, et al. (2012). Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur. J. Cancer 48: 3378-3385.
12. Tassone P, Tagliaferri P, Perricelli A, Blotta S, et al. (2003). BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88: 1285-1291.
13. Tiseo M, Bordi P, Bortesi B, Boni L, et al. (2013). ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br. J. Cancer 108: 1695-1703.
14. van Duin M, de Wit J, Odijk H, Westerveld A, et al. (1986). Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 44: 913-923.
15. illiam WN Jr, Lin HY, Lee JJ, Lippman SM, et al. (2009). Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 136: 701-709.
16. Yan D, Wei P, An G and Chen W (2013). Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J. Cardiothorac. Surg. 8: 149.
17. Yang Y, Xie Y and Xian L (2013). Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum-and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J. Exp. Clin. Cancer Res. 32: 15.
18. Yuanming L, Lineng Z, Baorong S, Junjie P, et al. (2013). BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer 13: 103.